OBJECTIVE: To evaluate the effect of post-treatment PSA kinetics on the prognosis of prostate cancer (PCa).
METHODS: We retrospectively reviewed the clinical data of 114 cases of locally advanced PCa treated by maximal androgen blockade (MAB) combined with brachytherapy, and analyzed the association of the changes in PSA kinetics with the prognosis of the patients.
RESULTS: The median survival time of the patients was 81 (15 - 144) months, with 1-, 3- and 5-year survival rates of 91. 23%, 78.07% and 68.42% , respectively. Univariate analysis indicated that the baseline PSA level, PSA nadir, the time of PSA decreasing to nadir, PSA doubling time, and the extent of PSA declining were all predictive factors for the survival time of the PCa patients. Multivariate analysis demonstrated that PSA nadir, the time of PSA decreasing to nadir, and the extent of PSA declining were three independent prognostic factors, which prolonged the long-term survival of the patients by 1.7, 3.2 and 6.8 times, respectively.
CONCLUSION: For locally advanced PCa treated by MAB combined with brachytherapy, PSA nadir < 1 micro g/L, the time to nadir < 3 months, and the extent of PSA declining >96% are independent prognostic factors.
Written by:
Luo Y, Wei NB, Zhao JH, Cui XH, Li MC, Lin YH, Hou Z, Han YL, Jiang YG. Are you the author?
Reference: Zhonghua Nan Ke Xue. 2014 Mar;20(3):229-33.
PubMed Abstract
PMID: 24738459
Article in Chinese.
UroToday.com Prostate Cancer Section
